MLYS (Mineralys Therapeutics) Common Stock: $0.01 Mil (As of Mar. 2026)


MLYS Mineralys Therapeutics Inc MLYS
35 GF Score
Price $26.96
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics Common Stock?

Mineralys Therapeutics MLYS +0.30% 35 Common Stock is $0.01 Mil as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Mineralys Therapeutics's quarterly common stock stayed the same from Sep. 2025 ($0.01 Mil) to Dec. 2025 ($0.01 Mil) and stayed the same from Dec. 2025 ($0.01 Mil) to Mar. 2026 ($0.01 Mil).

Mineralys Therapeutics's annual common stock increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.01 Mil) and increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.01 Mil).

Mineralys Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Common Stock Chart

Mineralys Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.00 0.00 0.00 0.01 0.01

Mineralys Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
MLYS
35GF Score
Mineralys Therapeutics Inc MLYS
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Mineralys Therapeutics (MLYS) has a Common Stock of $0.01 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Mineralys Therapeutics and its competitors.
Is Mineralys Therapeutics' Common Stock too high?
Mineralys Therapeutics' current Common Stock is $0.01 Mil. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Common Stock compare to VCEL and NRIX?
Mineralys Therapeutics' Common Stock of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Common Stock of $0.01 Mil. The current Common Stock is $0.01 Mil. Mineralys Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Common Stock is $0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score

Get the complete analysis for MLYS

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.96
Price